Medtronic Enters Leadless Pacemaker Competition With Micra CE Mark
This article was originally published in The Gray Sheet
Executive Summary
The firm’s ultra-small leadless pacing system has been cleared to launch in Europe, where it will face off with St. Jude’s Nanostim, which is slowly recovering from a pause in implants in 2014.
You may also be interested in...
Medtronic Goes Small With Leadless Pacer, Cardiac Monitor
The firm announced the first U.S. implant for its investigational Micra transcatheter, leadless pacing system, and the global launch of its miniature Reveal LINQ implantable cardiac monitor.
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”